<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01292057</url>
  </required_header>
  <id_info>
    <org_study_id>NIH P50 AA010761</org_study_id>
    <secondary_id>P50AA010761</secondary_id>
    <nct_id>NCT01292057</nct_id>
  </id_info>
  <brief_title>Aripiprazole Effects on Alcohol Drinking and Craving</brief_title>
  <official_title>Impulsivity and Drinking/Craving: Effect of a Dopamine Stabilizer Medication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether aripiprazole (marketed dopamine stabilizer)
      is effective in reducing of alcohol craving and drinking compared to placebo depending on
      participant's baseline level of impulsivity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-treatment seeking individuals meeting criteria for alcohol dependence (N=120) will be
      recruited through advertisement and paid for their participation. Subjects will have blood
      drawn for DNA analysis of various brain dopamine system genes. Alcoholics, after baseline
      evaluation, will be assigned through urn randomization to one of two experimental groups,
      depending on their baseline level of impulsivity, in which they will receive either
      aripiprazole (up to 15 mg/day) or an identical placebo. Subjects will take the study drug or
      placebo for 8 days (day 1-6 being the natural observation period). After a minimum of 24
      hours of abstinence from alcohol (day 7-8) they will undergo an alcohol administration
      (priming dose) and motivated free choice drinking procedure (on day 8). Alcoholic subjects
      will receive a brief counseling session at the end of the study to enhance their awareness of
      problem drinking and to motivate them to seek treatment. Referral for treatment will be
      offered.

      Each subject will undergo a functional MRI (functional magnetic resonance imaging) brain scan
      with cue stimulation on day 7, on the evening before the alcohol administration paradigm.
      fMRI (functional magnetic resonance) imaging brain imaging technology will be used to
      determine if alcoholics treated with aripiprazole differ in alcohol cue-induced activity in
      the nucleus accumbens. It is hypothesized that aripiprazole will reduce nucleus accumbens
      activation to alcohol cues compared to placebo.

      Whether dopamine system genetic differences will be predict drinking, nucleus accumbens
      activity, and aripiprazole response will be explored.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Number of Drinks Per Day During Natural (Usual Environment) Conditions</measure>
    <time_frame>6-day observation period</time_frame>
    <description>&quot;Natural&quot; alcohol consumption period -- drinks per day consumed during the 6-day observation period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Number of Drinks Consumed in Bar Lab</measure>
    <time_frame>2 hours during the bar lab paradigm</time_frame>
    <description>This measure refers to a &quot;bar lab&quot; paradigm in which individuals received an initial &quot;priming&quot; drink of alcohol, targeted to produce a breath alcohol concentration (BrAC) of 30 mg%, and could then choose to consume up to 8 additional drinks, each targeted to produce a BrAC of 15 mg%, during the subsequent 2 hours. Thus, the total number of drinks consumed could range between 0 and 8.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>Aripiprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Aripiprazole(up to 15 mg/day) for 8 days</description>
    <arm_group_label>Aripiprazole</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match active drug Aripiprazole for 8 days</description>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 21 - 40 (to focus on an age group still on a trajectory of increasing alcohol
             consumption).

          2. Meets the DSM IV criteria for current alcohol dependence including criterion 3 and/or
             4 &quot;loss of control over drinking&quot; or &quot;the inability to cut-down or stop drinking&quot;.

          3. Currently not engaged in, and does not want treatment for, alcohol related problems.

          4. Able to read and understand questionnaires and informed consent.

          5. Lives within 50 miles of the study site.

          6. Able to maintain abstinence for two days (without the aid of detoxification
             medications) as determined by self report and breathalyzer measurements.

        Inclusion for fMRI (functional magnetic resonance imaging) Imaging:

          1. Does not have metal objects in the head/neck.

          2. Does not have a history of claustrophobia leading to significant clinical anxiety
             symptoms.

        Exclusion Criteria:

          1. Currently meets DSM IV criteria for any other psychoactive substance dependence
             disorder.

          2. Any psychoactive substance use (except marijuana and nicotine) within the last 30 days
             by self-report and urine drug screen. For marijuana, no use within the last seven days
             by verbal report and negative (or decreasing) urine THC (tetrahydrocannabinol) levels.

          3. Meets DSM IV criteria for current axis I disorders of major depression, panic
             disorder, obsessive compulsive disorder, post traumatic stress syndrome, bipolar
             affective disorder, schizophrenia, dissociate disorders and eating disorders, any
             other psychotic disorder or organic mental disorder.

          4. Has current suicidal ideation or homicidal ideation.

          5. Need for maintenance or acute treatment with any psychoactive medication including
             anti-seizure medications and medications for ADHD (attention deficit hyperactivity
             disorder .

          6. Currently taking medication known to affect alcohol intake (e.g., disulfiram,
             naltrexone, acamprosate, topiramate).

          7. Clinically significant medical problems such as cardiovascular, renal, GI, or
             endocrine problems that would impair participation or limit medication ingestion.

          8. Past history of alcohol related medical illness such as gastrointestinal bleeding,
             pancreatitis, peptic ulcer, hepatic cirrhosis or alcoholic hepatitis.

          9. Hepatocellular disease indicated by elevations of SGPT (ALT) or SGOT (AST) greater
             than 2.5 times normal at screening.

         10. Females of childbearing potential who are pregnant (by urine HCG), nursing, or who are
             not using a reliable form of birth control.

         11. Has current charges pending for a violent crime (not including DUI (Driving Under
             Intoxication) related offenses).

         12. Does not have a stable living situation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Anton, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolian</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina, Institute of Psychiatry, Center for Drug and Alcohol Programs</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/</url>
    <description>Alcoholism</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp</url>
    <description>Ethanol</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp</url>
    <description>Aripiprazole</description>
  </link>
  <link>
    <url>http://clinicaltrials.gov/ct2/info/fdalinks</url>
    <description>Clinical trials</description>
  </link>
  <reference>
    <citation>Anton RF, Schacht JP, Voronin KE, Randall PK. Aripiprazole Suppression of Drinking in a Clinical Laboratory Paradigm: Influence of Impulsivity and Self-Control. Alcohol Clin Exp Res. 2017 Jul;41(7):1370-1380. doi: 10.1111/acer.13417. Epub 2017 Jun 5.</citation>
    <PMID>28493623</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2011</study_first_submitted>
  <study_first_submitted_qc>February 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2011</study_first_posted>
  <results_first_submitted>June 8, 2017</results_first_submitted>
  <results_first_submitted_qc>June 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 7, 2017</results_first_posted>
  <last_update_submitted>July 7, 2017</last_update_submitted>
  <last_update_submitted_qc>July 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Raymond F. Anton</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Alcohol</keyword>
  <keyword>Aripiprazole</keyword>
  <keyword>Impulsivity</keyword>
  <keyword>Alcoholism</keyword>
  <keyword>drinking</keyword>
  <keyword>treatment</keyword>
  <keyword>craving</keyword>
  <keyword>brain imaging</keyword>
  <keyword>genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aripiprazole</title>
          <description>Medication
Aripiprazole: Aripiprazole(up to 15 mg/day) for 8 days</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>Placebo: Placebo to match active drug Aripiprazole for 8 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aripiprazole</title>
          <description>Medication
Aripiprazole: Aripiprazole(up to 15 mg/day) for 8 days</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>Placebo: Placebo to match active drug Aripiprazole for 8 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="95"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.5" spread="5.6"/>
                    <measurement group_id="B2" value="27.0" spread="5.3"/>
                    <measurement group_id="B3" value="26.8" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Drinks Per Day During Natural (Usual Environment) Conditions</title>
        <description>&quot;Natural&quot; alcohol consumption period -- drinks per day consumed during the 6-day observation period</description>
        <time_frame>6-day observation period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole</title>
            <description>Medication
Aripiprazole: Aripiprazole(up to 15 mg/day) for 8 days</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo: Placebo to match active drug Aripiprazole for 8 days</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Drinks Per Day During Natural (Usual Environment) Conditions</title>
          <description>&quot;Natural&quot; alcohol consumption period -- drinks per day consumed during the 6-day observation period</description>
          <units>standard drinks</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="0.4"/>
                    <measurement group_id="O2" value="6.4" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Drinks Consumed in Bar Lab</title>
        <description>This measure refers to a &quot;bar lab&quot; paradigm in which individuals received an initial &quot;priming&quot; drink of alcohol, targeted to produce a breath alcohol concentration (BrAC) of 30 mg%, and could then choose to consume up to 8 additional drinks, each targeted to produce a BrAC of 15 mg%, during the subsequent 2 hours. Thus, the total number of drinks consumed could range between 0 and 8.</description>
        <time_frame>2 hours during the bar lab paradigm</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole</title>
            <description>Medication
Aripiprazole: Aripiprazole(up to 15 mg/day) for 8 days</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo: Placebo to match active drug Aripiprazole for 8 days</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Drinks Consumed in Bar Lab</title>
          <description>This measure refers to a &quot;bar lab&quot; paradigm in which individuals received an initial &quot;priming&quot; drink of alcohol, targeted to produce a breath alcohol concentration (BrAC) of 30 mg%, and could then choose to consume up to 8 additional drinks, each targeted to produce a BrAC of 15 mg%, during the subsequent 2 hours. Thus, the total number of drinks consumed could range between 0 and 8.</description>
          <units>bar lab drinks</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.4"/>
                    <measurement group_id="O2" value="4.5" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 days</time_frame>
      <desc>Adverse event defined as any symptom rated &quot;moderate&quot; or &quot;severe&quot; on a 21-item physical symptom checklist. Items from the checklist were: trouble sleeping, daytime sleepiness, nervousness, irritability, trouble concentrating, feeling depressed, abdominal pain, nausea/vomiting, constipation, joint pain, headache, dizziness, low energy, skin rash, ears ringing, vision blurry, itching, increased libido, decreased libido, difficulty reaching orgasm, and inability to reach orgasm.</desc>
      <group_list>
        <group group_id="E1">
          <title>Aripiprazole</title>
          <description>Medication
Aripiprazole: Aripiprazole(up to 15 mg/day) for 8 days</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>Placebo: Placebo to match active drug Aripiprazole for 8 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Trouble sleeping</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Daytime sleepiness</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Trouble concentrating</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Low energy</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling depressed</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Increased libido</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Decreased libido</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joseph Schacht, Ph.D.</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>(843) 792-7497</phone>
      <email>schacht@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

